Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomics of Psychotropic Medications in Psychiatric Disorders
NCT03907124Phase 4Withdrawn
- Sponsor
- Oregon Health & Science University
- Start
- Jun 2019
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in schizophrenia, major depressive disorder (MDD), bipolar affective disorder (BAD) and 1 more, sponsored by Oregon Health & Science University. Primary endpoints: Positive Subscale of Positive and Negative Syndrome Scale at 15 minutes and Behavioral Assessment of Pain Screening Instrument at 10 minutes. Planned start Jun 2019; status: withdrawn.
02
Conditions
schizophreniamajor depressive disorder (MDD)bipolar affective disorder (BAD)chronic pain
Beyond the preview
Go deeper on NCT03907124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907124.